Oxford Biosystems has been a supplier of products for the investigation of bone and cartilage metabolism for many years. Our products are sources from internationally recognised manufacturers and supported by their technical expertise gained through collaboration with scientists around the world.
Bones are continuously undergoing a dynamic process of resorption and absorption known as bone metabolism. This continual process is essential for the maintenance of healthy bone mass and micro-architecture. Signalling pathways on which bone metabolism rely include the action of several hormones, including osteocalcin, parathyroid hormone (PTH) and Vitamin D. The measurement of additional biomarkers including Sclerostin, Dickkopf-1 (DKK-1), Osteoprotegerin (OPG), free soluble RANKL and Cathepsin K provides useful information relating to osteoclast and osteoblast development.
Accelerated bone mass resorption can occur to women in postmenopausal years. Osteoporosis is a disease characterised by low bone density and reduced structural strength of the bone, leading to increased risk of bone fracture. Osteoporosis affects approximately 30% of postmenopausal women in the US and Europe and it is estimated that around the world 1 in 3 women and 1 in 5 men are at risk of osteoporotic fracture.
Cartilage is a connective tissue found in many areas of the body, including joints between bones (articular cartilage). Individuals whose cartilage is affected suffer from joint disease (arthritis) which is mainly degenerative and causes arthritis/osteoarthritis (OA), but also inflammatory arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
These bone related biomarkers are useful for monitoring bone metabolism in several clinical conditions:
- During peri- and post menopause
- During Hormone Replacement Therapy
- Patients with Growth Hormone deficiency
- Monitoring depressed bone formation in Multiple Myeloma
- Monitoring bone metastases in breast, prostate or lung cancer
- Investigation of chronic kidney disease
Chronic Kidney Disease – Mineral Bone Disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:
- Abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism
- Abnormalities in bone turnover, mineralisation, volume, linear growth or strength
- Vascular or other soft tissue calcification
Chronic kidney disease (CKD) is an international public health problem affecting 5–10% of the world population. As kidney function declines, there is a progressive deterioration in mineral homeostasis, with a disruption of concentrations of phosphorus and calcium, and changes in circulating levels of parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D),1,25-dihydroxyvitamin D (1,25(OH)2D).
We offer an extensive range of kits and reagents for both clinical investigation and research in the field of bone and cartilage metabolism. Product information is available in the downloadable brochures below, or please contact us directly to discuss your specific assay requirements.
- For further information please see page on Vitamin D.